Myviolet (Drospirenone, Ethinylestradiol)

Drospirenone is a synthetic progestogen with anti‑mineralocorticoid and anti‑androgenic properties, while ethinylestradiol is a potent estrogen. Together they suppress the hypothalamic‑pituitary‑gonadal axis, preventing the luteinizing hormone surge that triggers ovulation. They also thicken cervical mucus and modify the endometrium, making implantation unlikely.

The dosing regimen for Myviolet is determined by the prescribing healthcare professional. Typically, the product is taken as one tablet daily at the same time each day, following the specific cycle schedule indicated on the prescription label. Patients should follow their prescriber’s instructions and not alter the regimen without medical advice.

Myviolet is intended for use only when pregnancy is not desired; it should be discontinued if pregnancy is confirmed. The safety of combined oral contraceptives during pregnancy has not been established, and they are generally not recommended. Limited data exist for use while breastfeeding, and clinicians usually advise alternative contraception during lactation.

To order Myviolet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details and any necessary import documentation.

Myviolet contains drospirenone, which offers anti‑mineralocorticoid and anti‑androgenic effects that may reduce water retention and improve acne compared with some other progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, but the side‑effect profile can differ, with a potentially lower incidence of certain hormonal side effects.

Myviolet tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiration date printed on the packaging.

Myviolet is taken orally, usually as a single tablet each day at the same time. The tablets are typically packaged for a 21‑day active phase followed by a 7‑day hormone‑free interval, during which withdrawal bleeding occurs. Patients should follow the specific cycle instructions provided by their prescriber.

The most serious risks include venous or arterial thromboembolism (such as deep‑vein thrombosis, pulmonary embolism, stroke, or myocardial infarction), hypertension, and severe liver disorders. Women should seek immediate medical attention if they experience unexplained leg pain, chest pain, severe headache, visual changes, or signs of liver dysfunction.

Myviolet is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant. It should also be avoided by smokers over 35 years of age and by individuals taking strong CYP3A4‑inducing medications that could reduce contraceptive effectiveness.